Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00586573 · ClinicalTrials.gov registry record · Phase 4
Open-Label Pilot Study of Namenda in Adult Subjects With ADHD and ADHD NOS
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 34
- Enrollment target
NCT00586573: Completed Phase 4 study, sponsored by Massachusetts General Hospital.
NCT00586573 is a Phase 4 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 34 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00586573, a Phase 4 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 34 participants
- Enrollment target
Study Summary
The primary objective of the study is to assess the efficacy and tolerability of a 12-week trial of memantine hydrochloride administered twice daily in 20 adults (ages 18-55) with ADHD and ADHD NOS. Improvement will be defined as: 1) changes from baseline on the investigator-rated DSM-IV based ADHD Rating Scale; 2) changes from baseline in a questionnaire aimed at assessing executive functions (BRIEF); and 3) changes from screening in a computerized neuropsychological battery (CANTAB). We hypothesize that memantine hydrochloride will be associated with improving ADHD symptoms and associated deficits in executive functions. We also expect that memantine will be well-tolerated with predictable adverse events.
Interventions
- DRUG memantine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2007-03 |
| Est. Completion | 2009-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00586573
The ClinicalTrials.gov registry entry for NCT00586573 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which memantine hydrochloride is the first listed.
NCT00586573 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00586573 about?
NCT00586573 is a clinical study titled "Open-Label Pilot Study of Namenda in Adult Subjects With ADHD and ADHD NOS". The primary objective of the study is to assess the efficacy and tolerability of a 12-week trial of memantine hydrochloride administered twice daily in 20 adults (ages 18-55) with ADHD and ADHD NOS. Improvement will be defined as: 1) changes from baseline on the investigator-rated DSM-IV based ADHD ...
What is the current status of trial NCT00586573?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 34 participants. The study started on 2007-03. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00586573?
The interventions under investigation include: memantine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00586573?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.